Urology Search
Urology Urology
benign%20prostatic%20hyperplasia
BENIGN PROSTATIC HYPERPLASIA
Benign prostatic hyperplasia (BPH) is a histopathological diagnosis characterized by epithelial cell & smooth muscle cell proliferation in the transition zone of the prostate leading to a non-malignant enlargement of the gland, which may result in lower urinary tract symptoms, including voiding and storage symptoms.
It is commonly called enlarged prostate.
Etiology is unknown but due to its similarity to the embryonic morphogenesis of the prostate has led to the hypothesis that BPH may be the result of "reawakening" in adulthood of embryonic induction processes.

Benign%20prostatic%20hyperplasia Signs and Symptoms

Introduction

  • Histopathological diagnosis characterized by epithelial cell and smooth muscle proliferation in the transition zone of the prostate leading to a non-malignant enlargement of the gland, which may result in lower urinary tract symptoms (LUTS), including voiding and storage symptoms
  • Common disease of aging men
  • Two phases where prostate doubles its size:
    • At puberty
    • 25 years old and beyond

Etiology

  • The exact cause of benign prostatic hyperplasia (BPH) is still not well understood

Signs and Symptoms

  • Dribbling at the end of urination
  • Nocturia
  • Pain after ejaculation or urination
  • Weak or interrupted urine stream
  • Trouble starting a urine stream
  • Urinary frequency
  • Urinary urgency
  • Urinary retention
  • Urinary incontinence
  • Urine with unusual smell or color

Risk Factors

  • Age 40 years old and older
  • Family history of benign prostatic hyperplasia (BPH)
  • Medical conditions such as obesity, heart and circulatory disease, type 2 diabetes mellitus (DM)
  • Lack of physical exercise
Editor's Recommendations
Most Read Articles
Ivermectin improves survival in COVID-19 patients with severe pulmonary involvement
21 Nov 2020
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
Mental health problems spell trouble for diabetics
6 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Empagliflozin not just another SGLT2i: Cardio-renal benefits extend to HF with or without diabetes
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Vitamin D deficient COVID-19 patients at risk of morbidity, mortality
3 days ago
Vitamin D deficiency may be a contributing factor to the mortality rate among patients with the novel coronavirus disease (COVID-19), reports a new study.